

Singhal lab

Team
Hello
Associate Professor of Surgery, Harvard Medical School
Co-Director, Boston Lymphatic Center
Director of Lymphatic Surgery, Beth Israel Deaconess Medical Center
Harvard Medical School
Dr. Dhruv Singhal completed all of his formal surgical training in Boston. He is Board Certified in General Surgery having completed his general surgery training at the Brigham and Women’s Hospital (Boston, MA). Dr. Singhal is also Board Certified in Plastic and Reconstructive Surgery having completed further training in plastic surgery in the Harvard Combined Plastic Surgery Program. He then pursued a fellowship in adult craniofacial surgery at the Chang Gung Memorial Hospital (Taipei, Taiwan) and microsurgery at the China Medical University Hospital (Taichung, Taiwan). Currently, Dr. Singhal serves as Co-Director of the Boston Lymphatic Center and the Director of Lymphatic Surgery at the Beth Israel Deaconess Medical Center (Boston, MA) and Associate Professor of Surgery at Harvard Medical School. Dr. Singhal was previously the Director of Microsurgery at the University of Florida (Gainesville, Florida).
​
Dr. Singhal’s clinical focus is cancer and trauma reconstruction. Dr. Singhal performs the entire gambit of breast reconstruction from oncoplastic procedures to perforator flap operations (e.g. DIEP flaps). Dr. Singhal is a pioneer in immediate lymphatic reconstruction for the prevention of lymphedema in high risk patients and performs liposuction, lymphovenous bypass, and lymph node transplantation for the treatment of chronic lymphedema.
​
Dr. Singhal’s research focus is on lymphatic reconstruction. He has also published extensively on breast reconstruction, the role of integrative medicine in the care of the plastic surgery patient, and surgical ergonomics. Over the past few years, Dr. Singhal has been the recipient of research grants from the Plastic Surgery Foundation, American Society of Reconstructive Microsurgeons, Lymphatic Education and Research Network, Osher Center for Integrative Medicine (Harvard Medical School), and most recently, an RO1 from the NIH/NHLBI.